首页> 外文OA文献 >Benzodiazepine use during hospitalization: automated identification of potential medication errors and systematic assessment of preventable adverse events
【2h】

Benzodiazepine use during hospitalization: automated identification of potential medication errors and systematic assessment of preventable adverse events

机译:住院期间使用苯二氮卓类药物:自动识别潜在的用药错误并系统评估可预防的不良事件

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE Benzodiazepines and "Z-drug" GABA-receptor modulators (BDZ) are among the most frequently used drugs in hospitals. Adverse drug events (ADE) associated with BDZ can be the result of preventable medication errors (ME) related to dosing, drug interactions and comorbidities. The present study evaluated inpatient use of BDZ and related ME and ADE. METHODS We conducted an observational study within a pharmacoepidemiological database derived from the clinical information system of a tertiary care hospital. We developed algorithms that identified dosing errors and interacting comedication for all administered BDZ. Associated ADE and risk factors were validated in medical records. RESULTS Among 53,081 patients contributing 495,813 patient-days BDZ were administered to 25,626 patients (48.3%) on 115,150 patient-days (23.2%). We identified 3,372 patient-days (2.9%) with comedication that inhibits BDZ metabolism, and 1,197 (1.0%) with lorazepam administration in severe renal impairment. After validation we classified 134, 56, 12, and 3 cases involving lorazepam, zolpidem, midazolam and triazolam, respectively, as clinically relevant ME. Among those there were 23 cases with associated adverse drug events, including severe CNS-depression, falls with subsequent injuries and severe dyspnea. Causality for BDZ was formally assessed as 'possible' or 'probable' in 20 of those cases. Four cases with ME and associated severe ADE required administration of the BDZ antagonist flumazenil. CONCLUSIONS BDZ use was remarkably high in the studied setting, frequently involved potential ME related to dosing, co-medication and comorbidities, and rarely cases with associated ADE. We propose the implementation of automated ME screening and validation for the prevention of BDZ-related ADE.
机译:目的苯二氮卓类和“ Z药” GABA受体调节剂(BDZ)是医院中最常用的药物。与BDZ相关的不良药物事件(ADE)可能是与剂量,药物相互作用和合并症有关的可预防药物错误(ME)的结果。本研究评估了BDZ及其相关ME和ADE在住院患者中的使用情况。方法我们在药物流行病学数据库中进行了一项观察性研究,该数据库来自三级护理医院的临床信息系统。我们开发了算法,该算法可为所有管理的BDZ识别剂量错误和交互喜剧。相关的ADE和危险因素已在病历中得到验证。结果在115,150个病人日(23.2%)的25,626例患者(48.3%)中,有5,513例患者贡献了495,813个病人日的BDZ。在严重的肾功能不全患者中,我们确定了3,372个患者日(占2.9%)的喜剧抑制BDZ代谢,而劳拉西m给药了1,197个患者(1.0%)。验证后,我们将分别涉及劳拉西m,唑吡坦,咪达唑仑和三唑仑的134例,56例,12例和3例分类为临床相关的ME。在这些病例中,有23例伴有不良药物事件,包括严重的CNS抑郁症,跌倒,随后的受伤和严重的呼吸困难。在其中20例中,BDZ的因果关系被正式评估为“可能”或“可能”。 4例ME并伴有严重ADE的患者需要给予BDZ拮抗剂氟马西尼。结论在研究环境中,BDZ的使用非常高,经常涉及与剂量,联合用药和合并症相关的潜在ME,很少伴有ADE病例。我们建议实施自动ME筛查和验证,以预防与BDZ相关的ADE。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号